Hereditary angioedema: is there a better future for treatment?
- PMID: 36868262
- DOI: 10.1016/S0140-6736(23)00438-5
Hereditary angioedema: is there a better future for treatment?
Conflict of interest statement
DG declares consultancies, speakers' fees, and travel or accommodation payments by Takeda, Biocryst, Pharming, Kalvista, and CSL Behring. NJ declares no competing interests.
Comment on
-
Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.Lancet. 2023 Apr 1;401(10382):1079-1090. doi: 10.1016/S0140-6736(23)00350-1. Epub 2023 Feb 28. Lancet. 2023. PMID: 36868261 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
